Towards sustainable pharmaceutical QC: micellar-UPLC strategy for concomitant analysis of a cardiovascular polypill with aniline and salicylic acid impurities.

Ahmed R Mohamed, Israa M Nour, Mohamed Badrawy, Eman Darweish

Abstract read

In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ahmed R MohamedPharmaceutical Chemistry Department, Faculty of Pharmacy, Egyptian Russian University, Badr City, 11829, Cairo, Egypt. ahmed-rabea@eru.edu.eg.

Israa M NourPharmaceutical Chemistry Department, Faculty of Pharmacy, Egyptian Russian University, Badr City, 11829, Cairo, Egypt.

Mohamed BadrawyPharmaceutical Chemistry Department, Faculty of Pharmacy, Egyptian Russian University, Badr City, 11829, Cairo, Egypt.

Eman DarweishPharmaceutical Chemistry Department, Faculty of Pharmacy, Egyptian Russian University, Badr City, 11829, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Medication compliance is a key factor in achieving positive health outcomes, and this is difficult for patients, especially the elderly, who need polytherapy. Therefore, pharmacy experts have devised a single-pill combination that combines more than one active pharmaceutical ingredient to treat multiple diseases and improve patient compliance with medication. Here, an affordable UPLC approach was designed for the estimation of a fixed-dose combination that cures hypertension, hyperlipidemia, and blood coagulation and subsequently prevents heart attacks. This combination includes four active ingredients: aspirin (ASR), atorvastatin calcium (ATC), metoprolol succinate (MES), and ramipril (RAP). The applied approach was devised to determine the mentioned drugs in their commercial dosage form and also in the presence of ASR's impurity (salicylic acid) and ATC's impurity (aniline). The target drugs were separated on a Kinetex

Indexed as

Aniline CompoundsDrug ContaminationSalicylic AcidAspirinAtorvastatinBulk DrugsChromatography, High Pressure LiquidDrug CombinationsMetoprololMicellesRamiprilanilineAniline CompoundsAspirinAtorvastatinBulk DrugsDrug CombinationsMetoprololMicellesRamiprilSalicylic AcidCardiovascular polypillDrug impuritiesMicellar UPLCWhiteness and greenness.

Identifiers

PMID41571691

DOI10.1038/s41598-025-27968-w

PMCPMC12830728

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.